19 December 2023Big PharmaMarisa Woutersen

Pharma industry pushes back on Biden’s ‘dangerous’ plan

The Biden administration’s proposals target price gouging triggers resistance | The move, which includes the consideration of march-in rights for taxpayer-funded drugs, may ‘jeopardise collaborative partnerships and hinder innovation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Pharma body attacks ‘vague’ march-in rights plan

8 February 2024 PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.

Americas

Bernie Sanders blasts big pharma for ‘ripping off’ patients

8 February 2024 Senator criticises patent thickets and ‘monopolies’ ahead of senate hearing convened to interrogate CEOs | Sales of MSD’s blockbuster cancer treatment Keytruda rival McDonald’s annual revenue, says report.

Big Pharma

Biden takes aim at big pharma in controversial plan

12 December 2023 US government takes on price gouging in latest raft of proposals | IP attorney says the “unfortunate decision” will deter future public-private collaboration | Move prompts concern over government's future use of march-in rights.

More on this story

article

Pharma body attacks ‘vague’ march-in rights plan

8 February 2024 PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.

Americas

Bernie Sanders blasts big pharma for ‘ripping off’ patients

Big Pharma

Biden takes aim at big pharma in controversial plan

More on this story

article

Pharma body attacks ‘vague’ march-in rights plan

8 February 2024 PhRMA says controversial draft framework misinterprets the Bayh-Dole Act and could undo years of success | FTC unanimously supports the proposal.

Americas

Bernie Sanders blasts big pharma for ‘ripping off’ patients

Big Pharma

Biden takes aim at big pharma in controversial plan